Where can I learn more about this study?
You can find more information about this study on the websites listed below. If more information
about the study results is available, it can also be found here.
X www.clinicaltrials.gov. Once you are on the website, type “NCT03459846”
into the search box and click “Search”.
X http://www.clinicaltrialsregister.eu. Once you are on the website, click “Home and
Search”, then type “2017-004556-27” in the search box and click “Search”.
X www.AstraZenecaClinicalTrials.com. Once you are on the website, type “D933IC00003”
into the search box, and click “Find a Study”.
Full Study Title: A Phase II, Randomized, Multicenter, Double-Blind, Comparative Global Study
to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line
Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer
AstraZeneca Protocol Number: D933IC00003
National Clinical Trials Number: NCT03459846
EudraCT Number: 2017-004556-27
AstraZeneca sponsored this study and has its headquarters at Cambridge, UK.
The phone number for the AstraZeneca Information Center is +1-877-240-9479.
Thank you
Clinical study participants belong to a large community of people who take part in
clinical research around the world. They help researchers answer important
health questions and find medical treatments for patients.
The Center for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organization focused on
educating and informing the public about clinical research participation. CISCRP is not involved in recruiting participants
for clinical studies, nor is it involved in conducting clinical studies.
CISCRP | One Liberty Square, Suite 1100 • Boston, MA 02109 | 1-877-MED-HERO | www.ciscrp.org
Version 2.0 2021_10_08
12 | Clinical Study Results